In contrast, Lee et al. reported a 33-year-old female with myalgia, generalized weakness, diplopia, and ptosis following the second dose of an mRNA-based COVID-19 vaccine, who developed thymic hyperplasia, as well as an absence of antibodies to AchR and muscle-specific tyrosine kinase (MuSK). The gene discussed is MUSK; the disease is Myalgia.